Long-term oncological outcomes from an early phase randomised controlled three-arm trial of open, Robotic, and Laparoscopic Radical Cystectomy (CORAL)

European Urology Dec 19, 2019

Khan MS, Omar K, Ahmed K, et al. - In the present study, the researchers assessed the 5-yr oncological results of individuals recruited into the randomised trial of Open, Laparoscopic and Robot Assisted Cystectomy (CORAL) and extracorporeal urinary diversion. They reviewed prospectively maintained database of 60 individuals with muscle-invasive bladder cancer (MIBC) or high-risk nonmuscle-invasive bladder cancer (HRNMIBC) who were previously randomised in the CORAL trial to receive open radical cystectomy (ORC), robotic-assisted radical cystectomy (RARC), or laparoscopic radical cystectomy (LRC). In total, 60 individuals with either MIBC (n = 38) or HRNMIBC (n = 21) were randomised in the CORAL trial to receive ORC, RARC, or LRC. Data reported that the 5-yr RFS was 60%, 58%, and 71%; 5-yr CSS was 64%, 68%, and 69%; and 5-yr OS was 55%, 65%, and 61% for ORC, RARC, and LRC, respectively. No difference was found in 5-yr RFS, CSS, and OS rates of patients who had ORC, RARC, and LRC for management of bladder cancer. Minimally invasive procedures have obtained oncological outcomes equal to ORC's gold standard. However, the study was based on the small sample size of a single institution.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay